The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites

Ivacaftor–lumacaftor and ivacaftor are two new breakthrough cystic fibrosis transmembrane conductance modulators. The interactions of ivacaftor and its two metabolites hydroxymethylivacaftor (iva-M1) and ivacaftorcarboxylate (iva-M6) with neurotransmitter receptors were investigated in radioligand b...

Full description

Bibliographic Details
Main Authors:	Elena K. Schneider, Rachel M. McQuade, Vincenzo C. Carbone, Felisa Reyes-Ortega, John W. Wilson, Brenda Button, Ayame Saito, Daniel P. Poole, Daniel Hoyer, Jian Li, Tony Velkov
Format:	Article
Language:	English
Published:	European Respiratory Society 2018-03-01
Series:	ERJ Open Research
Online Access:	http://openres.ersjournals.com/content/4/1/00127-2017.full

Similar Items

Efectividad de TEZACAFTOR/IVACAFTOR+IVACAFTOR en fibrosis quística
by: Paula Del Río Ortega
Published: (2022-03-01)

Efectividad de TEZACAFTOR/IVACAFTOR+IVACAFTOR en fibrosis quística
by: Paula Del Río Ortega
Published: (2022-03-01)

Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
by: Guido Veit, et al.
Published: (2020-09-01)

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
by: Joseph M. Pilewski, et al.
Published: (2020-09-01)

A rapid RP-HPLC method for the simultaneous estimation of Ivacaftor and Tezacaftor and in silico study of their metabolitic products
by: Madhuri Donakonda, et al.
Published: (2021-06-01)

Mu and Delta Opioid Receptors Are Coexpressed and Functionally Interact in the Enteric Nervous System of the Mouse ColonSummary
by: Jesse J. DiCello, et al.
Published: (2020-01-01)

Bridging for lung transplantation with lumacaftor/ivacaftor
by: Søren Sperling Pedersen, et al.
Published: (2018-06-01)

Synthesis and Evaluation of Ivacaftor Derivatives with Reduced Lipophilicity
by: Melissa Iazzi, et al.
Published: (2023-11-01)

Ivacaftor: A Novel Mutation Modulating Drug
by: Harit Kapoor, et al.
Published: (2014-11-01)

Cities fit to live in and how, we can make them happen/
by: McQuade, Walter
Published: (1971)

World Histories of Big Data Policing
by: Brendan McQuade
Published: (2021-03-01)

Review of "Digital Labour and Karl Marx," by Christian Fuchs
by: Brendan McQuade
Published: (2015-08-01)

Mundo Nuevo: el discurso político en una revista intelectual de los sesenta
by: Frank McQuade
Published: (2016-04-01)

Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats
by: Jiří Pozniak, et al.
Published: (2024-02-01)

Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis
by: Katherine B. Hisert, et al.
Published: (2020-04-01)

Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor
by: Argyri Petrocheilou, et al.
Published: (2020-01-01)

Beneficial Effects of Capsaicin in Disorders of the Central Nervous System
by: Michał Pasierski, et al.
Published: (2022-04-01)

Trajectory optimization in the presence of constraints
by: McQuade, Timothy E
Published: (2008)

Dynamic control of a one-dimensional beam structure in the presence of distributed unsteady loads
by: McQuade, Peter David
Published: (2017)

Challenges in quantifying the clear effect of malnutrition on diarrhoeal deaths
by: Elizabeth T Rogawski McQuade
Published: (2020-02-01)

Digit ratio links prenatal hormone exposure with adult lung function
by: Denise Brooks McQuade
Published: (2014-06-01)

An LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin
by: Huiya Yuan, et al.
Published: (2021-12-01)

Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
by: Julie Mésinèle, et al.
Published: (2022-02-01)

Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety in cystic fibrosis
by: Lijia Zhang, et al.
Published: (2022-12-01)

Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
by: Burkhard Tümmler, et al.
Published: (2023-03-01)

The use of targeted therapy lumacaftor/ivacaftor in patients with cystic fibrosis
by: A. G. Chermensky, et al.
Published: (2022-04-01)

Sustained Glycemic Control With Ivacaftor in Cystic Fibrosis–Related Diabetes
by: Francis Christian MD, et al.
Published: (2019-04-01)

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
by: O&rsquo;Reilly R, et al.
Published: (2013-08-01)

Understanding and managing cybercrime /
by: 265593 McQuade, Samuel C.
Published: (2006)

Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA)
by: Firas Kreidieh, et al.
Published: (2024-04-01)

Identifying climate shocks in Young Lives communities: estimating weather conditions using a global gridded time series
by: McQuade, G, et al.
Published: (2024)

Turn-on fluorescent probes for detecting nitric oxide in biology
by: McQuade, Lindsey Elizabeth, 1981-
Published: (2010)

Secretion Systems and Secreted Proteins in Gram-Negative Entomopathogenic Bacteria: Their Roles in Insect Virulence and Beyond
by: Rebecca McQuade, et al.
Published: (2018-06-01)

Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor
by: Meng Liu, et al.
Published: (2023-12-01)

Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States
by: Dolly Sharma, et al.
Published: (2018-09-01)

Experience of using lumacaftor/ivacaftor in children with cystic fibrosis in the Astrakhan region
by: A. R. Kosareva, et al.
Published: (2022-09-01)

Structure of ABCB1/P-Glycoprotein in the Presence of the CFTR Potentiator Ivacaftor
by: Alessandro Barbieri, et al.
Published: (2021-11-01)

Ivacaftor: Five‐year outcomes in the West of Scotland cystic fibrosis population
by: Yasmin Al‐Din, et al.
Published: (2023-05-01)

Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations
by: László Csanády, et al.
Published: (2019-06-01)

Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
by: Connett GJ
Published: (2019-07-01)